

Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

In this article (Clin Cancer Res 2014;20:233–45), which was published in the January 1, 2014, issue of *Clinical Cancer Research* (1), the affiliation for Dr. Jordi Rodon was listed incorrectly. Dr. Rodon's affiliation should read as follows: Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain. The publisher regrets this error.

Reference

1. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Braña I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014;20:233–45.

Published online May 1, 2015.

doi: 10.1158/1078-0432.CCR-15-0185

©2015 American Association for Cancer Research.